Aadi Bioscience, Inc. (NASDAQ:AADI) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Aadi Bioscience, Inc. (NASDAQ:AADIGet Rating) have been assigned a consensus rating of “Buy” from the six research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $43.50.

A number of research analysts have weighed in on the company. HC Wainwright decreased their price objective on Aadi Bioscience from $49.00 to $48.00 and set a “buy” rating on the stock in a report on Monday, April 11th. Piper Sandler decreased their price objective on Aadi Bioscience from $50.00 to $30.00 in a report on Thursday, May 12th.

Shares of AADI stock opened at $14.67 on Friday. The stock’s fifty day moving average is $15.46 and its two-hundred day moving average is $18.75. The firm has a market capitalization of $307.22 million, a P/E ratio of -1.23 and a beta of 1.56. Aadi Bioscience has a fifty-two week low of $11.00 and a fifty-two week high of $49.80.

Aadi Bioscience (NASDAQ:AADIGet Rating) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.02. During the same period in the previous year, the business posted ($0.90) earnings per share. As a group, equities research analysts predict that Aadi Bioscience will post -2.85 earnings per share for the current year.

In other news, insider Neil Desai sold 3,550 shares of Aadi Bioscience stock in a transaction on Friday, March 18th. The stock was sold at an average price of $20.07, for a total transaction of $71,248.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. 7.10% of the stock is owned by insiders.

Several large investors have recently modified their holdings of AADI. VR Adviser LLC acquired a new stake in shares of Aadi Bioscience during the 3rd quarter worth about $44,919,000. BVF Inc. IL acquired a new stake in shares of Aadi Bioscience during the 3rd quarter worth about $33,689,000. Rock Springs Capital Management LP acquired a new stake in shares of Aadi Bioscience during the 3rd quarter worth about $22,459,000. RTW Investments LP acquired a new stake in shares of Aadi Bioscience during the 3rd quarter worth about $21,336,000. Finally, Decheng Capital Management III Cayman LLC acquired a new stake in shares of Aadi Bioscience during the 1st quarter worth about $8,932,000. 62.56% of the stock is owned by hedge funds and other institutional investors.

Aadi Bioscience Company Profile (Get Rating)

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.

Recommended Stories

Analyst Recommendations for Aadi Bioscience (NASDAQ:AADI)

Want More Great Investing Ideas?

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.